MDxHealth SA
MDXHHealthcareNASDAQDiagnostics & Research · Last scanned Sep 7, 2026
Scan Results
Daily timeframePart of the healthcare sector, MDxHealth SA (MDXH) is listed under Diagnostics & Research. At a $71.4M market cap, MDxHealth SA ranks as a micro-cap company within healthcare. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Market Cap
$71.4M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-1.97
EPS (TTM)
$-0.71
EPS (Fwd)
$-0.38
ROE
—
ROA
-9.8%
Cash
$19.2M
Total Debt
$105.8M
Free CF
-$17.4M
52W Change
-78.9%
Annual Financials
Cash vs Debt
Where MDXH stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MDXH finished 57.49% below its 150-day moving average ($1.67) and 66.51% below its 200-day moving average ($2.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDXH overbought or oversold?
At the September 3, 2026 close, MDXH's RSI(14) was 67.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MDxHealth SA carries $105.8M in total debt against $19.2M in cash reserves — debt is roughly 5.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$17.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $37.1M (2022) to $107.9M (2025), reflecting a 191% increase over the period.
MDxHealth SA carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MDXH's risk profile alongside its fundamentals and technical indicators provides a more complete picture.